Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
165 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Post-Operative Pain - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Post-Operative Pain - Pipeline Review, H2 2014', provides an overview of the Post-Operative Pain's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Post-Operative Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Operative Pain and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Post-Operative Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Post-Operative Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Post-Operative Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Post-Operative Pain pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post-Operative Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post-Operative Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Post-Operative Pain Overview 11 Therapeutics Development 12 Pipeline Products for Post-Operative Pain - Overview 12 Pipeline Products for Post-Operative Pain - Comparative Analysis 13 Post-Operative Pain - Therapeutics under Development by Companies 14 Post-Operative Pain - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Post-Operative Pain - Products under Development by Companies 20 Post-Operative Pain - Companies Involved in Therapeutics Development 23 A. Menarini Industrie Farmaceutiche Riunite Srl 23 AcelRx Pharmaceuticals, Inc. 24 Adynxx, Inc. 25 AngioChem Inc. 26 Aoxing Pharmaceutical Company, Inc 27 Boehringer Ingelheim GmbH 28 Cara Therapeutics, Inc. 29 Chong Kun Dang Pharmaceutical Corp. 30 Cytogel Pharma, LLC 31 DURECT Corporation 32 Echo Pharmaceuticals B.V. 33 Encore Therapeutics Inc. 34 Flexion Therapeutics, Inc. 35 Galleon Pharmaceuticals 36 GW Pharmaceuticals plc 37 Heron Therapeutics, Inc. 38 Hospira, Inc. 39 Immupharma Plc 40 Laboratorios Del Dr. Esteve S.A. 41 Medtronic, Inc. 42 Ocular Therapeutix, Inc. 43 Omeros Corporation 44 Orbis Biosciences, Inc. 45 Orion Oyj 46 Pfizer Inc. 47 Pharmazz, Inc. 48 PhytoHealth Corporation 49 Recro Pharma, Inc. 50 Rottapharm SpA 51 Takeda Pharmaceutical Company Limited 52 Trevena, Inc. 53 UMeWorld Limited 54 Post-Operative Pain - Therapeutics Assessment 55 Assessment by Monotherapy Products 55 Assessment by Combination Products 56 Assessment by Target 57 Assessment by Mechanism of Action 59 Assessment by Route of Administration 61 Assessment by Molecule Type 63 Drug Profiles 65 (bupivacaine hydrochloride + meloxicam) - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 (dexketoprofen trometamol + tramadol hydrochloride) - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 (ketoprofen + amitriptyline + oxymetazoline) - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 (ketorolac tromethamine + phenylephrine) - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 AM-4 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 ANG-2002 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 ARX-01 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 ARX-8028 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 ARX-8203 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 AYX-1 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 BI-1026706 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 bupivacaine hydrochloride - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 bupivacaine hydrochloride SR - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 buprenorphine hydrochloride ER - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 centhaquine - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 CKD-943 - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 CMX-020 - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 CR-4056 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 CR-845 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 Cyt-1010 - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 dexamethasone acetate SR - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 dexmedetomidine hydrochloride - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 diclofenac sodium - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 dronabinol - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 E-52862 - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 fadolmidine hydrochloride - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 FX-007 - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 GAL-044 - Drug Profile 106 Product Description 106 Mechanism of Action 106 R&D Progress 106 GIBH-1014 - Drug Profile 107 Product Description 107 Mechanism of Action 107 R&D Progress 107 grapiprant - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 IPP-102199 - Drug Profile 110 Product Description 110 Mechanism of Action 110 R&D Progress 110 ketamine hydrochloride ER - Drug Profile 111 Product Description 111 Mechanism of Action 111 R&D Progress 111 MDT-10013 - Drug Profile 112 Product Description 112 Mechanism of Action 112 R&D Progress 112 nabiximols - Drug Profile 113 Product Description 113 Mechanism of Action 113 R&D Progress 113 nalbuphine hydrochloride - Drug Profile 116 Product Description 116 Mechanism of Action 116 R&D Progress 116 ropivacaine - Drug Profile 117 Product Description 117 Mechanism of Action 117 R&D Progress 117 ropivacaine ER - Drug Profile 118 Product Description 118 Mechanism of Action 118 R&D Progress 118 tilidine hydrochloride - Drug Profile 120 Product Description 120 Mechanism of Action 120 R&D Progress 120 tramadol hydrochloride - Drug Profile 121 Product Description 121 Mechanism of Action 121 R&D Progress 121 TRV-130 - Drug Profile 123 Product Description 123 Mechanism of Action 123 R&D Progress 123 VVZ-149 - Drug Profile 124 Product Description 124 Mechanism of Action 124 R&D Progress 124 Post-Operative Pain - Recent Pipeline Updates 125 Post-Operative Pain - Dormant Projects 153 Post-Operative Pain - Discontinued Products 155 Post-Operative Pain - Product Development Milestones 156 Featured News & Press Releases 156 Nov 17, 2014: Trevena Announces Positive Top-Line Results from Phase 2a/b Study of TRV130 in Acute Postoperative Pain 156 Oct 30, 2014: Omidria Granted Pass-Through Reimbursement Status from CMS 158 Oct 08, 2014: Ocular Therapeutix Completes Enrollment in Phase 3 Sustained Release Dexamethasone Trials for Post-Operative Inflammation and Pain 158 Oct 08, 2014: Trevena Announces Early Completion of Enrollment of Phase 2a/b Study of TRV130 in Postoperative Pain 159 Sep 16, 2014: Trevena Granted Key U.S. Composition of Matter Patent for TRV130 160 Sep 04, 2014: Recro Pharma Provides Clinical Strategy Update Following Interim Analysis for Phase IIb Clinical Trial of Dex-IN 160 Jul 16, 2014: Adynxx Initiates Phase 2 Dose-Ranging Study of AYX1, Lead Compound for the Prevention of Post-Surgical Pain 161 May 14, 2014: Heron Therapeutics Reports Positive Results for Post-Surgical Pain Program 161 May 02, 2014: Trevena Presents Results from Phase 1b Trial of Injectable Analgesic TRV130 at American Society of Pain Annual Meeting 162 May 01, 2014: Trevena Initiates Phase 2 Study of TRV130 in Acute Postoperative Pain 163 Appendix 164 Methodology 164 Coverage 164 Secondary Research 164 Primary Research 164 Expert Panel Validation 164 Contact Us 165 Disclaimer 165
List of Tables Number of Products under Development for Post-Operative Pain, H2 2014 12 Number of Products under Development for Post-Operative Pain - Comparative Analysis, H2 2014 13 Number of Products under Development by Companies, H2 2014 15 Number of Products under Development by Companies, H2 2014 (Contd..1) 16 Comparative Analysis by Late Stage Development, H2 2014 17 Comparative Analysis by Clinical Stage Development, H2 2014 18 Comparative Analysis by Early Stage Development, H2 2014 19 Products under Development by Companies, H2 2014 20 Products under Development by Companies, H2 2014 (Contd..1) 21 Products under Development by Companies, H2 2014 (Contd..2) 22 Post-Operative Pain - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2014 23 Post-Operative Pain - Pipeline by AcelRx Pharmaceuticals, Inc., H2 2014 24 Post-Operative Pain - Pipeline by Adynxx, Inc., H2 2014 25 Post-Operative Pain - Pipeline by AngioChem Inc., H2 2014 26 Post-Operative Pain - Pipeline by Aoxing Pharmaceutical Company, Inc, H2 2014 27 Post-Operative Pain - Pipeline by Boehringer Ingelheim GmbH, H2 2014 28 Post-Operative Pain - Pipeline by Cara Therapeutics, Inc., H2 2014 29 Post-Operative Pain - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2014 30 Post-Operative Pain - Pipeline by Cytogel Pharma, LLC, H2 2014 31 Post-Operative Pain - Pipeline by DURECT Corporation, H2 2014 32 Post-Operative Pain - Pipeline by Echo Pharmaceuticals B.V., H2 2014 33 Post-Operative Pain - Pipeline by Encore Therapeutics Inc., H2 2014 34 Post-Operative Pain - Pipeline by Flexion Therapeutics, Inc., H2 2014 35 Post-Operative Pain - Pipeline by Galleon Pharmaceuticals, H2 2014 36 Post-Operative Pain - Pipeline by GW Pharmaceuticals plc, H2 2014 37 Post-Operative Pain - Pipeline by Heron Therapeutics, Inc., H2 2014 38 Post-Operative Pain - Pipeline by Hospira, Inc., H2 2014 39 Post-Operative Pain - Pipeline by Immupharma Plc, H2 2014 40 Post-Operative Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2014 41 Post-Operative Pain - Pipeline by Medtronic, Inc., H2 2014 42 Post-Operative Pain - Pipeline by Ocular Therapeutix, Inc., H2 2014 43 Post-Operative Pain - Pipeline by Omeros Corporation, H2 2014 44 Post-Operative Pain - Pipeline by Orbis Biosciences, Inc., H2 2014 45 Post-Operative Pain - Pipeline by Orion Oyj, H2 2014 46 Post-Operative Pain - Pipeline by Pfizer Inc., H2 2014 47 Post-Operative Pain - Pipeline by Pharmazz, Inc., H2 2014 48 Post-Operative Pain - Pipeline by PhytoHealth Corporation, H2 2014 49 Post-Operative Pain - Pipeline by Recro Pharma, Inc., H2 2014 50 Post-Operative Pain - Pipeline by Rottapharm SpA, H2 2014 51 Post-Operative Pain - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 52 Post-Operative Pain - Pipeline by Trevena, Inc., H2 2014 53 Post-Operative Pain - Pipeline by UMeWorld Limited, H2 2014 54 Assessment by Monotherapy Products, H2 2014 55 Assessment by Combination Products, H2 2014 56 Number of Products by Stage and Target, H2 2014 58 Number of Products by Stage and Mechanism of Action, H2 2014 60 Number of Products by Stage and Route of Administration, H2 2014 62 Number of Products by Stage and Molecule Type, H2 2014 64 Post-Operative Pain Therapeutics - Recent Pipeline Updates, H2 2014 125 Post-Operative Pain - Dormant Projects, H2 2014 153 Post-Operative Pain - Discontinued Products, H2 2014 155
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.